{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:44:41Z","timestamp":1790415881264,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"crossref"}]},{"name":"LogicBio Therapeutics."},{"name":"Alexion, AstraZeneca Rare Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gene-based editing can potentially correct the genetic defect in methylmalonic acidemia (MMA). SUNRISE, a first-in-human phase 1\/2 open-label study, evaluated the safety\/tolerability (primary endpoints) of liver-targeted hLB-001 in four pediatric participants (ages 20-114 months) with mitochondrial methylmalonyl-CoA mutase (MMUT)\u2013deficient MMA. We designed a single-infusion adeno-associated viral capsid (hLB-001) to nondisruptively integrate functional\n                    <jats:italic>MMUT<\/jats:italic>\n                    at the 3\u2032 end of the albumin (\n                    <jats:italic>ALB<\/jats:italic>\n                    ) locus to produce both albumin and MMUT. All four participants experienced at least one treatment-emergent adverse event. Three participants had treatment-emergent serious adverse events of cytokine release syndrome (one participant) and thrombotic microangiopathy (two participants); all resolved during the trial. Biologic activity, clinical efficacy, and 1-year survival were secondary endpoints. MMUT expression (measured by 2A-tagged ALB biomarker expression) increased in two participants over two years, confirming homology-based integration and positive selection of transgenic cells. However, serum methylmalonic acid (sMMA), serum FGF21, serum methylcitric acid (sMCA), and propionate oxidation remained abnormal in all four participants. All participants were alive at 1 year and at database lock. SUNRISE was terminated due to lack of efficacy. These results provide proof-of-concept for use of liver-targeted gene editing without nucleases for MMA and other genetic metabolic disorders. ClinicalTrials.gov identifier: NCT04581785\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Target journal<\/jats:bold>\n                    :\n                    <jats:italic>Gene Therapy (Springer Nature)<\/jats:italic>\n                  <\/jats:p>","DOI":"10.1038\/s41434-026-00609-1","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:56:10Z","timestamp":1774886170000},"page":"345-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["First-in-human nuclease-free homologous recombination-dependent gene editing in pediatric patients with methylmalonic acidemia: results of a phase 1\/2 study"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9580-9747","authenticated-orcid":false,"given":"Jirair K.","family":"Bedoyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gruskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Payton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Chereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene Scott","family":"Swenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2799-2615","authenticated-orcid":false,"given":"Mark A.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Vockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"609_CR1","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/jimd.12617","volume":"46","author":"PE Head","year":"2023","unstructured":"Head PE, Meier JL, Venditti CP. New insights into the pathophysiology of methylmalonic acidemia. J Inherit Metab Dis. 2023;46:436\u201349.","journal-title":"J Inherit Metab Dis"},{"key":"609_CR2","unstructured":"Manoli I, Sloan JL, Venditti CP Isolated Methylmalonic Acidemia. Aug 16, 2005 [Updated Sep 8, 2022]. In: Adam M, Feldman J, Mirzaa G, editors. GeneReviews\u00ae [Internet]: Seattle, WA: University of Washington, Seattle; 1993-2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1231\/."},{"key":"609_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1063-z","volume":"14","author":"T Almasi","year":"2019","unstructured":"Almasi T, Guey LT, Lukacs C, Csetneki K, Voko Z, Zelei T. Systematic literature review and meta-analysis on the epidemiology of methylmalonic acidemia (MMA) with a focus on MMA caused by methylmalonyl-CoA mutase (mut) deficiency. Orphanet J Rare Dis. 2019;14:84.","journal-title":"Orphanet J Rare Dis"},{"key":"609_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ymgme.2014.07.009","volume":"113","author":"BL Therrell Jr","year":"2014","unstructured":"Therrell BL Jr, Lloyd-Puryear MA, Camp KM, Mann MY. Inborn errors of metabolism identified via newborn screening: ten-year incidence data and costs of nutritional interventions for research agenda planning. Mol Genet Metab. 2014;113:14\u201326.","journal-title":"Mol Genet Metab"},{"key":"609_CR5","doi-asserted-by":"publisher","first-page":"1110942","DOI":"10.3389\/fnins.2023.1110942","volume":"17","author":"T Chen","year":"2023","unstructured":"Chen T, Gao Y, Zhang S, Wang Y, Sui C, Yang L. Methylmalonic acidemia: neurodevelopment and neuroimaging. Front Neurosci. 2023;17:1110942.","journal-title":"Front Neurosci"},{"key":"609_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/jimd.12370","volume":"44","author":"P Forny","year":"2021","unstructured":"Forny P, Horster F, Ballhausen D, Chakrapani A, Chapman KA, Dionisi-Vici C, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision. J Inherit Metab Dis. 2021;44:566\u201392.","journal-title":"J Inherit Metab Dis"},{"key":"609_CR7","doi-asserted-by":"publisher","first-page":"100592","DOI":"10.1016\/j.trre.2020.100592","volume":"35","author":"YZ Jiang","year":"2021","unstructured":"Jiang YZ, Zhou GP, Wu SS, Kong YY, Zhu ZJ, Sun LY. Safety and efficacy of liver transplantation for methylmalonic acidemia: a systematic review and meta-analysis. Transpl Rev. 2021;35:100592.","journal-title":"Transpl Rev"},{"key":"609_CR8","doi-asserted-by":"publisher","first-page":"100337","DOI":"10.1016\/j.gim.2022.11.005","volume":"25","author":"K Sen","year":"2023","unstructured":"Sen K, Burrage LC, Chapman KA, Ginevic I, Mazariegos GV, Graham BH, et al. Solid organ transplantation in methylmalonic acidemia and propionic acidemia: a points to consider statement of the American College of Medical Genetics and Genomics. Genet Med. 2023;25:100337.","journal-title":"Genet Med"},{"key":"609_CR9","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1089\/hum.2019.113","volume":"30","author":"RJ Chandler","year":"2019","unstructured":"Chandler RJ, Venditti CP. Gene therapy for methylmalonic acidemia: past, present, and future. Hum Gene Ther. 2019;30:1236\u201344.","journal-title":"Hum Gene Ther"},{"key":"609_CR10","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/hep.31570","volume":"73","author":"RJ Chandler","year":"2021","unstructured":"Chandler RJ, Venturoni LE, Liao J, Hubbard BT, Schneller JL, Hoffmann V, et al. Promoterless, nuclease-free genome editing confers a growth advantage for corrected hepatocytes in mice with methylmalonic acidemia. Hepatology. 2021;73:2223\u201337.","journal-title":"Hepatology"},{"key":"609_CR11","doi-asserted-by":"publisher","first-page":"e0274774","DOI":"10.1371\/journal.pone.0274774","volume":"17","author":"S Zhang","year":"2022","unstructured":"Zhang S, Bastille A, Gordo S, Ramesh N, Vora J, McCarthy E, et al. Novel AAV-mediated genome editing therapy improves health and survival in a mouse model of methylmalonic acidemia. PLoS One. 2022;17:e0274774.","journal-title":"PLoS One"},{"key":"609_CR12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature12875","volume":"506","author":"L Lisowski","year":"2014","unstructured":"Lisowski L, Dane AP, Chu K, Zhang Y, Cunningham SC, Wilson EM, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature. 2014;506:382\u20136.","journal-title":"Nature"},{"key":"609_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature13864","volume":"517","author":"A Barzel","year":"2015","unstructured":"Barzel A, Paulk NK, Shi Y, Huang Y, Chu K, Zhang F, et al. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature. 2015;517:360\u20134.","journal-title":"Nature"},{"key":"609_CR14","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","volume":"30","author":"M Muhuri","year":"2022","unstructured":"Muhuri M, Levy DI, Schulz M, McCarty D, Gao G. Durability of transgene expression after rAAV gene therapy. Mol Ther. 2022;30:1364\u201380.","journal-title":"Mol Ther"},{"key":"609_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2022.06.011","volume":"137","author":"LE Venturoni","year":"2022","unstructured":"Venturoni LE, Chandler RJ, Liao J, Hoffmann V, Ramesh N, Gordo S, et al. Growth advantage of corrected hepatocytes in a juvenile model of methylmalonic acidemia following liver directed adeno-associated viral mediated nuclease-free genome editing. Mol Genet Metab. 2022;137:1\u20138.","journal-title":"Mol Genet Metab"},{"key":"609_CR16","doi-asserted-by":"crossref","unstructured":"de Lima JGS, Lanza DCF 2A and 2A-like sequences: distribution in different virus species and applications in biotechnology. Viruses. 2021;13:2160.","DOI":"10.3390\/v13112160"},{"key":"609_CR17","unstructured":"ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi) prescribing information. Novartis Gene Therapies Inc.;2023."},{"key":"609_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/humu.23013","volume":"37","author":"P Forny","year":"2016","unstructured":"Forny P, Schnellmann AS, Buerer C, Lutz S, Fowler B, Froese DS, et al. Molecular genetic characterization of 151 Mut-type methylmalonic aciduria patients and identification of 41 novel mutations in MUT. Hum Mutat. 2016;37:745\u201354.","journal-title":"Hum Mutat"},{"key":"609_CR19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1172\/JCI115597","volume":"89","author":"AM Crane","year":"1992","unstructured":"Crane AM, Jansen R, Andrews ER, Ledley FD. Cloning and expression of a mutant methylmalonyl coenzyme A mutase with altered cobalamin affinity that causes mut- methylmalonic aciduria. J Clin Invest. 1992;89:385\u201391.","journal-title":"J Clin Invest"},{"key":"609_CR20","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/hmg\/6.9.1457","volume":"6","author":"J Janata","year":"1997","unstructured":"Janata J, Kogekar N, Fenton WA. Expression and kinetic characterization of methylmalonyl-CoA mutase from patients with the mut- phenotype: evidence for naturally occurring interallelic complementation. Hum Mol Genet. 1997;6:1457\u201364.","journal-title":"Hum Mol Genet"},{"key":"609_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0130-8","volume":"9","author":"MR Baumgartner","year":"2014","unstructured":"Baumgartner MR, Horster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman KA, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130.","journal-title":"Orphanet J Rare Dis"},{"key":"609_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5414\/CNP66063","volume":"66","author":"I Pela","year":"2006","unstructured":"Pela I, Gasperini S, Pasquini E, Donati MA. Hyperkalemia after acute metabolic decompensation in two children with vitamin B12-unresponsive methylmalonic acidemia and normal renal function. Clin Nephrol. 2006;66:63\u20136.","journal-title":"Clin Nephrol"},{"key":"609_CR23","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.1007\/s00431-023-05221-8","volume":"182","author":"G Tar\u00e7\u0131n","year":"2023","unstructured":"Tar\u00e7\u0131n G, Ahmadzada S, Sayg\u0131l\u0131 S, Kaya A, Aktu\u011flu Zeybek A, Ercan O. Evaluating renin and aldosterone levels in children with organic acidemia-therapeutic experience with fludrocortisone. Eur J Pediatr. 2023;182:5447\u201353.","journal-title":"Eur J Pediatr"},{"key":"609_CR24","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00467-009-1188-8","volume":"24","author":"J-C Davin","year":"2009","unstructured":"Davin J-C, Buter N, Groothoff J, van Wijk J, Bouts A, Strain L, et al. Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatr Nephrol. 2009;24:1757\u201360.","journal-title":"Pediatr Nephrol"},{"key":"609_CR25","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood-2007-04-084533","volume":"111","author":"CJ Fang","year":"2008","unstructured":"Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship THJ, et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood. 2008;111:624\u201332.","journal-title":"Blood"},{"key":"609_CR26","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","volume":"22","author":"TK Kishimoto","year":"2022","unstructured":"Kishimoto TK, Samulski RJ. Addressing high dose AAV toxicity - \u2018one and done\u2019 or \u2018slower and lower\u2019? Expert Opin Biol Ther. 2022;22:1067\u201371.","journal-title":"Expert Opin Biol Ther"},{"key":"609_CR27","doi-asserted-by":"publisher","first-page":"107612","DOI":"10.1016\/j.ymgme.2023.107612","volume":"139","author":"J Vockley","year":"2023","unstructured":"Vockley J, Burton B, Jurecka A, Ganju J, Leiro B, Zori R, et al. Challenges and strategies for clinical trials in propionic and methylmalonic acidemias. Mol Genet Metab. 2023;139:107612.","journal-title":"Mol Genet Metab"},{"key":"609_CR28","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.2013.285873","volume":"311","author":"ML Batshaw","year":"2014","unstructured":"Batshaw ML, Groft SC, Krischer JP. Research into rare diseases of childhood. JAMA. 2014;311:1729\u201330.","journal-title":"JAMA"},{"key":"609_CR29","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s12072-020-10066-6","volume":"14","author":"MJ Caldez","year":"2020","unstructured":"Caldez MJ, Bjorklund M, Kaldis P. Cell cycle regulation in NAFLD: when imbalanced metabolism limits cell division. Hepatol Int. 2020;14:463\u201374.","journal-title":"Hepatol Int"},{"key":"609_CR30","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1093\/nar\/gkh703","volume":"32","author":"N Saleh-Gohari","year":"2004","unstructured":"Saleh-Gohari N, Helleday T. Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res. 2004;32:3683\u20138.","journal-title":"Nucleic Acids Res"},{"key":"609_CR31","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/sj.gt.3301259","volume":"7","author":"A Ferrer","year":"2000","unstructured":"Ferrer A, Wells KE, Wells DJ. Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy. Gene Ther. 2000;7:1439\u201346.","journal-title":"Gene Ther"},{"key":"609_CR32","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1073\/pnas.1617726114","volume":"114","author":"R Calcedo","year":"2017","unstructured":"Calcedo R, Somanathan S, Qin Q, Betts MR, Rech AJ, Vonderheide RH, et al. Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for alpha-1-antitrypsin deficiency. Proc Natl Acad Sci USA. 2017;114:1655\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"609_CR33","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/jimd.12636","volume":"46","author":"I Manoli","year":"2023","unstructured":"Manoli I, Gebremariam A, McCoy S, Pass AR, Gagn\u00e9 J, Hall C, et al. Biomarkers to predict disease progression and therapeutic response in isolated methylmalonic acidemia. J Inherit Metab Dis. 2023;46:554\u201372.","journal-title":"J Inherit Metab Dis"},{"key":"609_CR34","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s41436-021-01143-8","volume":"23","author":"I Manoli","year":"2021","unstructured":"Manoli I, Pass AR, Harrington EA, Sloan JL, Gagne J, McCoy S, et al. 1-(13)C-propionate breath testing as a surrogate endpoint to assess efficacy of liver-directed therapies in methylmalonic acidemia (MMA). Genet Med. 2021;23:1522\u201333.","journal-title":"Genet Med"},{"key":"609_CR35","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1089\/hum.2023.194","volume":"35","author":"E Kropf","year":"2024","unstructured":"Kropf E, Markusic DM, Majowicz A, Mingozzi F, Kuranda K. Complement system response to adeno-associated virus vector gene therapy. Hum Gene Ther. 2024;35:425\u201338.","journal-title":"Hum Gene Ther"},{"key":"609_CR36","doi-asserted-by":"publisher","first-page":"e173510","DOI":"10.1172\/JCI173510","volume":"134","author":"SM Salabarria","year":"2024","unstructured":"Salabarria SM, Corti M, Coleman KE, Wichman MB, Berthy JA, D\u2019Souza P, et al. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies. J Clin Invest. 2024;134:e173510.","journal-title":"J Clin Invest"},{"key":"609_CR37","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","volume":"6","author":"J Guillou","year":"2022","unstructured":"Guillou J, de Pellegars A, Porcheret F, Fremeaux-Bacchi V, Allain-Launay E, Debord C, et al. Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Adv. 2022;6:4266\u201370.","journal-title":"Blood Adv"},{"key":"609_CR38","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","volume":"95","author":"A Le Clech","year":"2019","unstructured":"Le Clech A, Simon-Tillaux N, Provot F, Delmas Y, Vieira-Martins P, Limou S, et al. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney Int. 2019;95:1443\u201352.","journal-title":"Kidney Int"},{"key":"609_CR39","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.ekir.2021.01.034","volume":"6","author":"S Timmermans","year":"2021","unstructured":"Timmermans S, Damoiseaux J, Werion A, Reutelingsperger CP, Morelle J, van Paassen P. Functional and genetic landscape of complement dysregulation along the spectrum of thrombotic microangiopathy and its potential implications on clinical outcomes. Kidney Int Rep. 2021;6:1099\u2013109.","journal-title":"Kidney Int Rep"},{"key":"609_CR40","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.ymthe.2025.03.041","volume":"33","author":"F Puzzo","year":"2025","unstructured":"Puzzo F, Kay MA. The deLIVERed promises of gene therapy: past, present, and future of liver-directed gene therapy. Mol Ther. 2025;33:1966\u201387.","journal-title":"Mol Ther"},{"key":"609_CR41","doi-asserted-by":"publisher","first-page":"809118","DOI":"10.3389\/fmed.2021.809118","volume":"8","author":"HKE Au","year":"2021","unstructured":"Au HKE, Isalan M, Mielcarek M. Gene therapy advances: a meta-analysis of AAV usage in clinical settings. Front Med. 2021;8:809118.","journal-title":"Front Med"},{"key":"609_CR42","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41417-021-00413-6","volume":"29","author":"S Maurya","year":"2022","unstructured":"Maurya S, Sarangi P, Jayandharan GR. Safety of adeno-associated virus-based vector-mediated gene therapy-impact of vector dose. Cancer Gene Ther. 2022;29:1305\u20136.","journal-title":"Cancer Gene Ther"},{"key":"609_CR43","unstructured":"U.S. Food and Drug Administration. Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) Meeting #70. Toxicity Risks of Adeno-associated Virus (AAV) Vectors for Gene Therapy (GT) - Briefing Document. Sep 2-3, 2021)."},{"key":"609_CR44","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","volume":"385","author":"LA George","year":"2021","unstructured":"George LA, Monahan PE, Eyster ME, Sullivan SK, Ragni MV, Croteau SE, et al. Multiyear factor VIII expression after AAV gene transfer for hemophilia A. N Engl J Med. 2021;385:1961\u201373.","journal-title":"N Engl J Med"},{"key":"609_CR45","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","volume":"22","author":"PB Shieh","year":"2023","unstructured":"Shieh PB, Kuntz NL, Dowling JJ, M\u00fcller-Felber W, B\u00f6nnemann CG, Seferian AM, et al. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial. Lancet Neurol. 2023;22:1125\u201339.","journal-title":"Lancet Neurol"},{"key":"609_CR46","unstructured":"ClinicalTrials.gov. Dose-finding study of SPK-8016 gene therapy in patients with hemophilia A to support evaluation in individuals with FVIII inhibitors - Results [updated February 23, 2024]. https:\/\/clinicaltrials.gov\/study\/NCT03734588?tab=results#adverse-events."},{"key":"609_CR47","first-page":"e129","volume":"36","author":"A Chakrapani","year":"2025","unstructured":"Chakrapani A, Baruteau J, Blackstone J, Yilmaz BS, Sreekantam S, Dorp LV, et al. First patient treated in the phase 1\u20132 trial of AAVLK03hOTC gene therapy for ornithine transcarbamylase deficiency in children. Hum Gene Ther. 2025;36:e129\u2013e557.","journal-title":"Hum Gene Ther"},{"key":"609_CR48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/hum.2022.29198.bfs","volume":"33","author":"A Philippidis","year":"2022","unstructured":"Philippidis A. After patient death, FDA places hold on Pfizer Duchenne muscular dystrophy gene therapy trial. Hum Gene Ther. 2022;33:111\u20135.","journal-title":"Hum Gene Ther"},{"key":"609_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.thromres.2020.06.016","volume":"194","author":"JW Yun","year":"2020","unstructured":"Yun JW, Oh J, Lee KO, Lee SJ, Kim JO, Kim NK, et al. Distinct genetic profile with recurrent population-specific missense variants in Korean adult atypical hemolytic uremic syndrome. Thromb Res. 2020;194:45\u201353.","journal-title":"Thromb Res"},{"key":"609_CR50","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jhep.2023.10.029","volume":"80","author":"MM M\u00fccke","year":"2024","unstructured":"M\u00fccke MM, Fong S, Foster GR, Lillicrap D, Miesbach W, Zeuzem S. Adeno-associated viruses for gene therapy - clinical implications and liver-related complications, a guide for hepatologists. J Hepatol. 2024;80:352\u201361.","journal-title":"J Hepatol"},{"key":"609_CR51","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.gie.2021.06.016","volume":"94","author":"RL Kruse","year":"2021","unstructured":"Kruse RL, Huang Y, Shum T, Bai L, Ding H, Wang ZZ, et al. Endoscopic-mediated, biliary hydrodynamic injection mediating clinically relevant levels of gene delivery in pig liver. Gastrointest Endosc. 2021;94:1119\u201330.","journal-title":"Gastrointest Endosc"},{"key":"609_CR52","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.gie.2018.06.022","volume":"88","author":"V Kumbhari","year":"2018","unstructured":"Kumbhari V, Li L, Piontek K, Ishida M, Fu R, Khalil B, et al. Successful liver-directed gene delivery by ERCP-guided hydrodynamic injection (with videos). Gastrointest Endosc. 2018;88:755\u201363.","journal-title":"Gastrointest Endosc"},{"key":"609_CR53","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1089\/hgtb.2014.140","volume":"26","author":"F Stoller","year":"2015","unstructured":"Stoller F, Schlegel A, Viecelli HM, Rufenacht V, Cesarovic N, Viecelli C, et al. Hepatocyte transfection in small pigs after weaning by hydrodynamic intraportal injection of naked DNA\/minicircle vectors. Hum Gene Ther Methods. 2015;26:181\u201392.","journal-title":"Hum Gene Ther Methods"},{"key":"609_CR54","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","volume":"28","author":"JL Shirley","year":"2020","unstructured":"Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther. 2020;28:709\u201322.","journal-title":"Mol Ther"},{"key":"609_CR55","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21:255\u201372.","journal-title":"Nat Rev Genet"},{"key":"609_CR56","doi-asserted-by":"publisher","first-page":"100300","DOI":"10.1016\/j.jhepr.2021.100300","volume":"3","author":"S Maestro","year":"2021","unstructured":"Maestro S, Weber ND, Zabaleta N, Aldabe R, Gonzalez-Aseguinolaza G. Novel vectors and approaches for gene therapy in liver diseases. JHEP Rep. 2021;3:100300.","journal-title":"JHEP Rep"},{"key":"609_CR57","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3390\/genes11080915","volume":"11","author":"CG Moscoso","year":"2020","unstructured":"Moscoso CG, Steer CJ. The evolution of gene therapy in the treatment of metabolic liver diseases. Genes. 2020;11:915\u201342.","journal-title":"Genes"},{"key":"609_CR58","doi-asserted-by":"publisher","first-page":"1106085","DOI":"10.3389\/fmed.2023.1106085","volume":"10","author":"EM Shitik","year":"2023","unstructured":"Shitik EM, Shalik IK, Yudkin DV. AAV- based vector improvements unrelated to capsid protein modification. Front Med. 2023;10:1106085.","journal-title":"Front Med"},{"key":"609_CR59","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3390\/pharmaceutics12100964","volume":"12","author":"Y Endo-Takahashi","year":"2020","unstructured":"Endo-Takahashi Y, Negishi Y. Microbubbles and nanobubbles with ultrasound for systemic gene delivery. Pharmaceutics. 2020;12:964.","journal-title":"Pharmaceutics"},{"key":"609_CR60","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","volume":"392","author":"K Musunuru","year":"2025","unstructured":"Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N Engl J Med. 2025;392:2235\u201343.","journal-title":"N Engl J Med"},{"key":"609_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48885-9","volume":"9","author":"OY Al-Dirbashi","year":"2019","unstructured":"Al-Dirbashi OY, Alfadhel M, Al-Thihli K, Al Dhahouri N, Langhans CD, Al Hammadi Z, et al. Assessment of methylcitrate and methylcitrate to citrate ratio in dried blood spots as biomarkers for inborn errors of propionate metabolism. Sci Rep. 2019;9:12366.","journal-title":"Sci Rep"},{"key":"609_CR62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cca.2018.09.017","volume":"487","author":"N Al Dhahouri","year":"2018","unstructured":"Al Dhahouri N, Langhans CD, Al Hammadi Z, Okun JG, Hoffmann GF, Al-Jasmi F, et al. Quantification of methylcitrate in dried urine spots by liquid chromatography tandem mass spectrometry for the diagnosis of propionic and methylmalonic acidemias. Clin Chim Acta. 2018;487:41\u20135.","journal-title":"Clin Chim Acta"},{"key":"609_CR63","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/jimd.12287","volume":"43","author":"E Maines","year":"2020","unstructured":"Maines E, Catesini G, Boenzi S, Mosca A, Candusso M, Dello Strologo L, et al. Plasma methylcitric acid and its correlations with other disease biomarkers: the impact in the follow up of patients with propionic and methylmalonic acidemia. J Inherit Metab Dis. 2020;43:1173\u201385.","journal-title":"J Inherit Metab Dis"},{"key":"609_CR64","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s10545-018-0244-6","volume":"41","author":"F Molema","year":"2018","unstructured":"Molema F, Jacobs EH, Onkenhout W, Schoonderwoerd GC, Langendonk JG, Williams M. Fibroblast growth factor 21 as a biomarker for long-term complications in organic acidemias. J Inherit Metab Dis. 2018;41:1179\u201387.","journal-title":"J Inherit Metab Dis"},{"key":"609_CR65","doi-asserted-by":"crossref","unstructured":"Manoli I, Sysol JR, Epping MW, Li L, Wang C, Sloan JL, et al. FGF21 underlies a hormetic response to metabolic stress in methylmalonic acidemia. JCI Insight. 2018;3:e124351.","DOI":"10.1172\/jci.insight.124351"},{"key":"609_CR66","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cca.2021.12.015","volume":"525","author":"A Abildgaard","year":"2022","unstructured":"Abildgaard A, Knudsen CS, Hoejskov CS, Greibe E, Parkner T. Reference intervals for plasma vitamin B12 and plasma\/serum methylmalonic acid in Danish children, adults and elderly. Clin Chim Acta. 2022;525:62\u20138.","journal-title":"Clin Chim Acta"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00609-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00609-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00609-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:03:21Z","timestamp":1780326201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00609-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["609"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00609-1","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JKB has nothing to disclose. TM became an employee of BioMarin Pharmaceutical, Inc., after the conduct of the trial. AS has nothing to disclose. HL has nothing to disclose. DG was Chief Medical Officer of LogicBio Therapeutics. MP was an employee of Alexion, AstraZeneca Rare Disease, and holds stock or stock options in AstraZeneca. MAK was a co-founder of LogicBio Therapeutics and served on the Board of Directors and Scientific Advisory Board, and as a consultant for LogicBio Therapeutics. FC is an employee of Alexion, AstraZeneca Rare Disease, and holds stock or stock options in AstraZeneca. ESS is an employee of Alexion, AstraZeneca Rare Disease, and holds stock or stock options in AstraZeneca. QL was an employee of Alexion, AstraZeneca Rare Disease, and holds stock or stock options in AstraZeneca. JV received research funding from LogicBio to conduct this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the IRB at each participating study site (University of Pittsburgh [MOD20010208-002]; Vanderbilt University [201305]; Seattle Children\u2019s Hospital [20203011]; Emory University [STUDY00002158]). All participants or their parents, guardians, or legal representatives provided written informed consent and assent. The study was performed in accordance with the current Good Clinical Practice Guideline of the International Council for Harmonisation and appropriate regulatory requirements. An independent data and safety monitoring board (DSMB) and sponsor medical monitor provided study oversight.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}